EP217609: Phase I started

Endotis began a double-blind, placebo-controlled, single ascending-dose, French Phase I trial to evaluate 1, 3 and 10 mg IV EP217609 in 40 healthy volunteers. Endotis has rights to EP217609 from Scher...